You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)中期收入約152.8億元 同比增長約0.5%
格隆匯 08-25 16:53

中國生物製藥(01177.HK)公吿,截至2023年6月30日止6個月中期業績,集團錄得收入約人民幣152.8億元,較去年同期增長約0.5%。2023年第二季度收入約人民幣86.3億元,較去年同期增長約30.0%。歸屬於母公司持有者盈利約人民幣12.59億元,較去年減少約34.5%。基於歸屬於母公司持有者盈利計算每股盈利約人民幣6.78分,較去年減少約34.2%。

7月21日,國家醫保局發佈了《談判藥品續約規則》《非獨家藥品競價規則》,新規明確了藥品納入常規目錄的管理規範,減輕了藥品新增適應症及續約的降價壓力,利好創新藥發展。3月29日,第八批國家藥品集中帶量採購在海南開標,共有39種藥品採購成功,擬中選藥品平均降價56%,集採已進入常態化、制度化管理階段。集團年收入5億以上的仿製藥產品(剔除獨家產品)均已納入集採範圍,集採風險已出清。

 集團在製藥業務方面繼續以發展專科治療領域相關產品為主,致力打造專科品牌。集團的主要治療領域包括抗腫瘤用藥、肝病用藥、呼吸系統用藥、外科╱鎮痛用藥、心腦血管用藥及其他產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account